Key Points
- CEO Amy Burroughs sold 71,339 shares on Jan. 5 at an average price of $38.10 for $2.718M, leaving her with 138,976 shares — a 33.92% reduction in her ownership stake.
- Analysts have grown bullish recently (examples: HC Wainwright to $60, Truist to $56, Mizuho to $54), and Terns holds a consensus rating of Moderate Buy with a consensus price target of $55.56.
- TERN is trading around $38.32 with a 52-week range of $1.87–$48.26, a market cap of about $3.45 billion, and institutional ownership of 98.26%.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider directly owned 50,365 shares of the company's stock, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Terns Pharmaceuticals Stock Performance
NASDAQ:TERN opened at $38.32 on Wednesday. The firm has a market cap of $3.45 billion, a P/E ratio of -37.20 and a beta of -0.28. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $48.26. The firm has a 50-day simple moving average of $30.87 and a two-hundred day simple moving average of $15.14.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. On average, equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms have commented on TERN. Barclays lifted their target price on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an "overweight" rating in a report on Tuesday, December 9th. Oppenheimer lifted their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an "outperform" rating in a report on Tuesday, December 9th. Mizuho upped their target price on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, December 9th. JMP Securities set a $35.00 price target on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. Finally, Citigroup reissued an "outperform" rating on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.56.
View Our Latest Analysis on TERN
Institutional Investors Weigh In On Terns Pharmaceuticals
A number of large investors have recently made changes to their positions in TERN. GAMMA Investing LLC increased its position in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company's stock valued at $35,000 after purchasing an additional 770 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Terns Pharmaceuticals during the second quarter valued at approximately $41,000. Canada Pension Plan Investment Board purchased a new stake in Terns Pharmaceuticals during the second quarter valued at approximately $46,000. LeConte Wealth Management LLC bought a new position in Terns Pharmaceuticals in the second quarter worth approximately $47,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Terns Pharmaceuticals in the first quarter worth approximately $51,000. 98.26% of the stock is currently owned by institutional investors.
Terns Pharmaceuticals Company Profile
(
Get Free Report)
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
